Wall Street expects Philip Morris International to report Q2 2026 revenue of $10.64 billion and adjusted EPS of $2.04, with shares trading near $192.98 relative to a $194.63 average analyst price target.
Investors are zeroed in on the continued expansion of the smoke-free portfolio, specifically the U.S. performance of ZYN nicotine pouches following a recent landmark FDA authorization for modified-risk marketing.
This transition is vital as smoke-free products now contribute approximately 43% of total net revenues, helping to offset the secular decline in traditional cigarette volumes.
Analysts will also look for updates on the U.S. launch of IQOS and the impact of the new ZYN ULTRA format on domestic oral nicotine market share.